Figure 6.
DNA damage and apoptosis in SK-LMS-1 and HT1080 xenografts. Graphs demonstrating the number of CD31+/γH2AX+/cleaved caspase-3+ cells (A) and CD31−/γH2AX+/cleaved caspase-3+ cells (B) in SK-LMS-1 tumours from each treatment group. (C) Immunofluorescence photos of tumours from each treatment group after staining for CD31 (green), γH2AX (white), cleaved caspase-3 (red), and nuclei (DAPI, 4',6-diamidino-2-phenylindole). Graphs demonstrating the number of CD31+/γH2AX+/cleaved caspase-3+ cells (D) and CD31−/γH2AX+/cleaved caspase-3+ cells (E) in HT1080 tumours from each treatment group. (E) Immunofluorescence photos of tumours from each treatment group after staining for CD31 (green), γH2AX (white), cleaved caspase-3 (red), and nuclei (DAPI). Bars represent standard deviation. Scale bar, 20 μm. **P<0.05 compared with all other groups.
